復星醫藥(02196.HK)以近16億人幣出售亞能生物29.02%股權
復星醫藥(02196.HK)公布,公司、亞能投資、前海志投於9月30日與買方Yaneng Bioscience訂立股權轉讓及增資協議,買方將以22.04億元人民幣(下同),向公司、亞能投資及前海志投收購亞能生物股權,當中以15.96億元作價向公司收購所持的29.02%亞能生物權益及復星診斷所持的金石醫檢所的100%股權。買方並將斥資3億元認購亞能生物新增註冊資本約63.46萬港元。
於股權轉讓及增資協議項下交易完成後,復星醫藥於亞能生物的持股將由50.1084%減少至19.9976%,並不再持有金石醫檢所股權;而買方Yaneng Bioscience於亞能生物的持股將增加至43.1722%。
倘建議出售完成,預計將為集團貢獻稅後收益約14億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.